CHMP Positive Opinion for Once-Daily Nevanac 3mg/ml (Nepafenac) Eye Drops in Europe

Source: Novartis

On June 24, 2016, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of once-daily Nevanac 3mg/ml (nepafenac) eye drops, suspension in Europe for the reduction in risk of postoperative macular edema associated with cataract surgery in diabetic patients, according to Novartis. Outside the European Union, Nevanac 3mg/ml is marketed as Ilevro.
Nevanac 3mg/ml is a once-daily non-steroidal anti-inflammatory (NSAID) ophthalmic suspension. It is already approved in Europe for prevention and treatment of pain and inflammation associated with cataract surgery. A lower concentration of nepafenac (Nevanac 1 mg/ml eye drops, suspension) is approved for both of the above indications but is administered 3 times daily.

Related Content